I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NIPQRppkgXSxdH;4bYNqfHliYYPzZZk> MUn+NVAxKM7:TR?= NFzTR2RFVVOR NGm2Z3ZKSzVyPUK2JI5O NE\PXnYzOTl4NEO0NC=>
RS4;11 NWjudppK[3m2b4TvfIlkcXS7IHHzd4F6 M2Dmb54yODBizszN M2jNUmROW09? NVS2[mVDUUN3ME2xPVIhdk1? MV6yNVk3PDN2MB?=
MOLM13 M37HXYN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml23glExOCEQvF2= M{L2dGROW09? MUPJR|UxRTF{MDDuUS=> NE[ybZAzOTl4NEO0NC=>
NOMO1 NV7Ed2s6[3m2b4TvfIlkcXS7IHHzd4F6 M3zxVJ4yODBizszN M3u2WGROW09? NYPpWHZjUUN3ME2xOUBvVQ>? MVKyNVk3PDN2MB?=
HEL M3zsNIN6fG:2b4jpZ4l1gSCjc4PhfS=> NGPPeoJ,OTByIN88US=> MVLEUXNQ NHLMTnhKSzVyPUGg{txO Mn3QNlE6PjR|NEC=
K562 NY\wPZpU[3m2b4TvfIlkcXS7IHHzd4F6 M1fhdJ4yODBizszN MVjEUXNQ MUHJR|UxRjFyMDFOwG0> NH61TIszOTl4NEO0NC=>
MEG01 M1\FUYN6fG:2b4jpZ4l1gSCjc4PhfS=> MXH+NVAxKM7:TR?= MlnzSG1UVw>? MUDJR|UxRTJ3IN88US=> NYL2R4xbOjF7NkSzOFA>
HL60 NYjV[lR5[3m2b4TvfIlkcXS7IHHzd4F6 M2nIep4yODBizszN MUjEUXNQ NYjsW|Q4UUN3ME24PVAhdk1? NVzx[3FtOjF7NkSzOFA>
MV4;11 MoLIRZBweHSxc3nzJIF{e2G7 NX;WWHFmhjFyMDFOwG0> MUXEUXNQ NWXBVlkxcW6mdXPld{BieG:ydH;zbZM> NYTLfWVZOjF7NkSzOFA>
MOLM13 MXrBdI9xfG:|aYOgZZN{[Xl? MonyglExOCEQvF2= M2Hhd2ROW09? NEXtS5dqdmS3Y3XzJIFxd3C2b4Ppdy=> M3PDO|IyQTZ2M{Sw
MV4;11 NEPHdHdHfW6ldHnvckBie3OjeR?= NXjpfpFMTE2VTx?= MYnk[YNz\WG|ZYOgeIhmKHKnY4L1bZRu\W62IH;mJGJTTDNxNDDhcoQhcW2yYXny[YQhemWlcoXpeI1mdnRib3[gR2RMQSCjbnSgVGFHOSC2bzD0bIUhfHKjboPjdolxfGmxbnHsJJN1[XK2IIPpeIU> NH;heZkzOTl4NEO0NC=>
PBMC MWPGeY5kfGmxbjDhd5NigQ>? M{DmPWROW09? MX\pcohq[mm2czDJUE03KHerdHigdGlEPTBib3[gOk44 M17jbFIzPDN5MUG1
A2 MXrGeY5kfGmxbjDhd5NigQ>? NXrxemZThjFyIN88US=> NWfWOIM1TE2VTx?= MUny[YFkfGm4YYTld{Bt[XSnboSgTGlXNTF? M3TX[|I{OjV3MkG4
A72 MYLGeY5kfGmxbjDhd5NigQ>? NVLqTVg3hjFyIN88US=> MkHFSG1UVw>? M3u4bJJm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= M2PRN|I{OjV3MkG4
BC1 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlP5glEh|ryP NVLNSohlTE2VTx?= MnHyTWM2OD1{MkCgcm0> NYK2PXhFOjN5OUK0OFg>
BC3 NVfuOHczT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFTzfmt,OSEQvF2= MV7EUXNQ M33SXmlEPTB;NE[wJI5O M4DOV|I{Pzl{NES4
BCBL1 NITP[oxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3PBVp4yKM7:TR?= M3\VdWROW09? NHLO[lBKSzVyPUOzNEBvVQ>? M2fqeVI{Pzl{NES4
BJAB MojGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHvpPVB,OSEQvF2= NUiwd45tTE2VTx?= NV6wdZpyUUN3ME25O|Ahdk1? MXSyN|c6OjR2OB?=
Namalwa MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUf+NUDPxE1? NIr6blZFVVOR NV\MWHAyUUN3ME25O|Ahdk1? Mnf4NlM4QTJ2NEi=
Jurkat MomwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4L2UJ4yKM7:TR?= MXLEUXNQ M1jXV2lEPTB;MUKyNEBvVQ>? NYO1dlNqOjN5OUK0OFg>
MM1S MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnjKglEh|ryP M2HlVmROW09? NGrGSppKSzVyPUe2NEBvVQ>? M3fRelI{Pzl{NES4
U266 NGK0fIRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXrJWGpHhjFizszN MnvuSG1UVw>? MnjjTWM2OD17NUCgcm0> M335XFI{Pzl{NES4
UM-PEL-1 M2H1O2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYn+NUDPxE1? MlvxSG1UVw>? NWqyWJZrUUN3ME2yNVAhdk1? M17iT|I{Pzl{NES4
UM-PEL-3 MofHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWqzZpF7hjFizszN NXjmVYdlTE2VTx?= NGTaPItKSzVyPUG4NEBvVQ>? NUK2e5Q5OjN5OUK0OFg>
BC1 M2G0W2Z2dmO2aX;uJIF{e2G7 Mnu3OVAxKG6P MmT4SG1UVw>? NXGwZ3licW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> MonkNlM4QTJ2NEi=
BC3 MUXGeY5kfGmxbjDhd5NigQ>? Ml\IOVAxKG6P MWnEUXNQ MWrpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 NE\hNY0zOzd7MkS0PC=>
BC1 M4[4NGZ2dmO2aX;uJIF{e2G7 MmPtPFAxKG6P NU[zXlZyTE2VTx?= NYXBXXBnemWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? NYLrXY9KOjN5OUK0OFg>
BC3 NHLaZ3JHfW6ldHnvckBie3OjeR?= NIHCdZc5ODBibl2= NFfpO|FFVVOR MWHy[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz M37ZelI{Pzl{NES4
H929 MVzGeY5kfGmxbjDhd5NigQ>? M1r1ep4yKM7:TR?= NXOwcY9ITE2VTx?= M4nZfIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NUnLUVJNOjR|M{W0PVk>
KMS12PE MWXGeY5kfGmxbjDhd5NigQ>? M4XRep4yKM7:TR?= M4L3VmROW09? NH3nbHRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NF:5RmIzPDN|NUS5PS=>
KMS12BM MmXMSpVv[3Srb36gZZN{[Xl? MmPOglEh|ryP NGDVTVBFVVOR Mn21bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M{PUZVI1OzN3NEm5
KMS18 NHzzfHZHfW6ldHnvckBie3OjeR?= NVu0THlNhjFizszN NGnme5VFVVOR MmHBbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M174dVI1OzN3NEm5
KMS11 M3PDOmZ2dmO2aX;uJIF{e2G7 Mm[0glEh|ryP NHvSWoZFVVOR M3zueolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= M4nGZ|I1OzN3NEm5
RPMI8226 NISwNY5HfW6ldHnvckBie3OjeR?= NYLxZ41LhjFizszN NWP0NWFqTE2VTx?= M3XuNYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NWe0dJpTOjR|M{W0PVk>
H929 NHPsOm1CeG:ydH;zbZMh[XO|YYm= MlnhglEh|ryP M3jo[GROW09? Mn;wbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NGOxfpYzPDN|NUS5PS=>
KMS12PE M4PkVWFxd3C2b4Ppd{Bie3OjeR?= NHLjXo1,OSEQvF2= M4DLT2ROW09? M17iUolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4LVUVI1OzN3NEm5
KMS12BM NGLOZ3FCeG:ydH;zbZMh[XO|YYm= M1P2SZ4yKM7:TR?= MXXEUXNQ MlXYbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M2mwSFI1OzN3NEm5
KMS18 NWj2ZWIzSXCxcITvd4l{KGG|c3H5 Mly4glEh|ryP MX;EUXNQ NHv0WJZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MofjNlQ{OzV2OUm=
KMS11 MnSzRZBweHSxc3nzJIF{e2G7 M2DwXp4yKM7:TR?= NGPhfoxFVVOR NInUPXRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEjSUZgzPDN|NUS5PS=>
RPMI8226 MX;BdI9xfG:|aYOgZZN{[Xl? MWr+NUDPxE1? NGjRbllFVVOR NE\RTGhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWn1e2ZbOjR|M{W0PVk>
U87MG NYiwfVNlTnWwY4Tpc44h[XO|YYm= M{jDOp4yOCEQvF2= NWixV2xmTE2VTx?= NHTaW2Vz\WS3Y3XzJHU5P02JIHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6wOUDPxE1? MX:yOFQ6PjN6MR?=
A172 NGTxdVRHfW6ldHnvckBie3OjeR?= NVnYUIluhjFyIN88US=> NInRZ4hFVVOR MonxdoVlfWOnczDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEGuNlgh|ryP MXeyOFQ6PjN6MR?=
SW1783 NYLXVlJwTnWwY4Tpc44h[XO|YYm= NYTEWINJhjFyIN88US=> MW\EUXNQ MYXy[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMj62PEDPxE1? M2nsSlI1PDl4M{ix
U87MG NIXTPGRHfW6ldHnvckBie3OjeR?= M2XGU54yOCEQvF2= M1frPWROW09? NV70fo5vcW6lcnXhd4V{KHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6geIhmKEdzL2OgeJJidnOrdHnvci=> M{\3eVI1PDl4M{ix
RAW267.4 M3PNe2Z2dmO2aX;uJIF{e2G7 M2\jPVEh|ryP MX\EUXNQ Mn;GdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM> MmX6NlQ5PTlyMEi=
RAW267.4 MYTGeY5kfGmxbjDhd5NigQ>? MX6xJO69VQ>? NF7JfllFVVOR NULZZW5pemWmdXPld{B1cGViYYPzc4Nq[XSrb36gZoV1f2WnbjDCVmQ1KGGwZDDhZ4V1gWyjdHXkJJA3PQ>? M{\ob|I1QDV7MEC4
Me007 MonLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkfLglExOCEQvF2= M1jOfmROW09? NWPpOJlUcW6qaXLpeJMhfGinIHfyc5d1cA>? MXWyOFkxPjF|Nx?=
SK-Mel-28 NGHWZlNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXj+NVAxKM7:TR?= M1X4U2ROW09? MUfpcohq[mm2czD0bIUh\3Kxd4To NX63b4hxOjR7ME[xN|c>
Mel-RMU MorpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFPzRVN,OTByIN88US=> Mm[2SG1UVw>? MWXpcohq[mm2czD0bIUh\3Kxd4To NWf1WGJYOjR7ME[xN|c>
Mel-JD M3Pke2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVP+NVAxKM7:TR?= NGm1PGFFVVOR MkHybY5pcWKrdIOgeIhmKGe{b4f0bC=> MW[yOFkxPjF|Nx?=
Mel-RM MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFnzUmF,OTByIN88US=> MVrEUXNQ M1rybIlvcGmkaYTzJJRp\SCpcn;3eIg> M4\Gb|I1QTB4MUO3
Me007 M1HKWmFxd3C2b4Ppd{Bie3OjeR?= M{LwNZ4yODBizszN NVu3T45TTE2VTx?= M2PmU4lv\HWlZYOgZZBweHSxc3nz M{j1PFI1QTB4MUO3
SK-Mel-28 NH7HVVRCeG:ydH;zbZMh[XO|YYm= NVLveJVNhjFyMDFOwG0> MYLEUXNQ M{TpZYlv\HWlZYOgZZBweHSxc3nz NH;ZeYYzPDlyNkGzOy=>
Mel-RMU NVXB[nlWSXCxcITvd4l{KGG|c3H5 MXz+NVAxKM7:TR?= NUfDO2tpTE2VTx?= M1\jd4lv\HWlZYOgZZBweHSxc3nz NG\6T|kzPDlyNkGzOy=>
Mel-JD NXXWSmM6SXCxcITvd4l{KGG|c3H5 MYn+NVAxKM7:TR?= MXfEUXNQ NUO0SlFScW6mdXPld{BieG:ydH;zbZM> MVKyOFkxPjF|Nx?=
Mel-RM MnXMRZBweHSxc3nzJIF{e2G7 NIPoRXZ,OTByIN88US=> MnPZSG1UVw>? M3vnbolv\HWlZYOgZZBweHSxc3nz NUfpWVl5OjR7ME[xN|c>
Me007 NUfsbld3TnWwY4Tpc44h[XO|YYm= NHfhXW4yOCEQvF2= NVPtS4VqTE2VTx?= Mnq1bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NVn1OZJtOjR7ME[xN|c>
SK-Mel-28 MoL5SpVv[3Srb36gZZN{[Xl? NHzYPJIyOCEQvF2= NELsXpdFVVOR MmnubY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NGLaSY0zPDlyNkGzOy=>
Mel-RMU MXHGeY5kfGmxbjDhd5NigQ>? NF;vR24yOCEQvF2= NHuwd2ZFVVOR MYTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MlzzNlQ6ODZzM{e=
Mel-JD NF3EeIhHfW6ldHnvckBie3OjeR?= M2nGSlExKM7:TR?= MmKzSG1UVw>? NEe4ZlFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? Mly1NlQ6ODZzM{e=
Mel-RM MoPPSpVv[3Srb36gZZN{[Xl? MXKxNEDPxE1? MWTEUXNQ NY\RWXl7cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz MmHYNlQ6ODZzM{e=
Me007 NFvr[5BHfW6ldHnvckBie3OjeR?= NXjrdY5HOTBizszN M{ntfmROW09? NX7uPWpkfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MVuyOFkxPjF|Nx?=
SK-Mel-28 Ml75SpVv[3Srb36gZZN{[Xl? MlnCNVAh|ryP M3KwfWROW09? NXiwd|VjfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> NE\hToQzPDlyNkGzOy=>
Mel-RMU NFnMWYxHfW6ldHnvckBie3OjeR?= NEPoSWwyOCEQvF2= MmDWSG1UVw>? MY\1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| NWrWWHFnOjR7ME[xN|c>
Mel-JD NI\qS4FHfW6ldHnvckBie3OjeR?= MoHWNVAh|ryP NH;hO49FVVOR NULuZWdtfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> NYfSOHZCOjR7ME[xN|c>
Mel-RM NGjUfFlHfW6ldHnvckBie3OjeR?= MVKxNEDPxE1? Mk[5SG1UVw>? MojmeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NIDSSFUzPDlyNkGzOy=>

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO slightly soluble or insoluble
Water slightly soluble or insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID